AR125416A1 - AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSOTROPHIES - Google Patents

AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSOTROPHIES

Info

Publication number
AR125416A1
AR125416A1 ARP220101055A ARP220101055A AR125416A1 AR 125416 A1 AR125416 A1 AR 125416A1 AR P220101055 A ARP220101055 A AR P220101055A AR P220101055 A ARP220101055 A AR P220101055A AR 125416 A1 AR125416 A1 AR 125416A1
Authority
AR
Argentina
Prior art keywords
sequence
nucleic acid
itr
capsid protein
acid vector
Prior art date
Application number
ARP220101055A
Other languages
Spanish (es)
Inventor
Arun Srivastava
Keyun Qing
Barry John Byrne
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of AR125416A1 publication Critical patent/AR125416A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan proteínas de la cápside de AAV modificadas, partículas, vectores de ácidos nucleicos y composiciones de las mismas, así como métodos para su uso. Reivindicación 1: Una proteína de la cápside que comprende una sustitución de aminoácido en una posición que corresponde a Y447, T494, K547, N665, y/o Y733 de la proteína de la cápside AAVrh74 de tipo salvaje de la SEQ ID Nº 1, en donde la proteína de la cápside es una proteína de la cápside serotipo AAVrh74, opcionalmente en donde la sustitución es Y447F, T494V, K547R, N665R, y/o Y733F. Reivindicación 3: La partícula de AAVrh74 de la reivindicación 2, que comprende además un vector de ácido nucleico, en donde el vector de ácido nucleico comprende una primera repetición terminal invertida (ITR) que comprende una primera secuencia D y una segunda ITR que comprende una segunda secuencia D, en donde la primera secuencia D o la segunda secuencia D se sustituye con una secuencia S, opcionalmente en donde la secuencia S comprende, consiste esencialmente en, o consiste en la secuencia de nucleótidos TATTAGATCTGATGGCCGCT (SEQ ID Nº 17). Reivindicación 4: La partícula de AAVrh74 de la reivindicación 2, que comprende además un vector de ácido nucleico, en donde el vector de ácido nucleico comprende una primera repetición terminal invertida (ITR) que comprende una primera secuencia D y una segunda ITR que comprende una segunda secuencia D, en donde la primera secuencia D y/o la segunda secuencia D se sustituye con un elemento de unión a receptor glucocorticoide (GRE), opcionalmente en donde el GRE comprende, consiste esencialmente en, o consiste en la secuencia de nucleótidos AGAACANNNTGTTCT (SEQ ID Nº 18), o su inverso o complemento inverso, en donde cada N es independientemente un T, C, G, o A.Modified AAV capsid proteins, particles, nucleic acid vectors, and compositions thereof, as well as methods for their use, are provided. Claim 1: A capsid protein comprising an amino acid substitution at a position corresponding to Y447, T494, K547, N665, and/or Y733 of the wild-type AAVrh74 capsid protein of SEQ ID NO:1, in where the capsid protein is a serotype AAVrh74 capsid protein, optionally where the substitution is Y447F, T494V, K547R, N665R, and/or Y733F. Claim 3: The rh74AAV particle of claim 2, further comprising a nucleic acid vector, wherein the nucleic acid vector comprises a first inverted terminal repeat (ITR) comprising a first D sequence and a second ITR comprising a second D sequence, wherein either the first D sequence or the second D sequence is substituted with an S sequence, optionally wherein the S sequence comprises, consists essentially of, or consists of the nucleotide sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 17). Claim 4: The rh74AAV particle of claim 2, further comprising a nucleic acid vector, wherein the nucleic acid vector comprises a first inverted terminal repeat (ITR) comprising a first D-sequence and a second ITR comprising a second D-sequence, wherein the first D-sequence and/or the second D-sequence is substituted with a glucocorticoid receptor (GRE) binding element, optionally wherein the GRE comprises, consists essentially of, or consists of the nucleotide sequence AGAACANNNTGTTCT (SEQ ID Nº 18), or its inverse or inverse complement, where each N is independently a T, C, G, or A.

ARP220101055A 2020-04-05 2022-04-22 AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSOTROPHIES AR125416A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063327410P 2020-04-05 2020-04-05
US202163179097P 2021-04-23 2021-04-23

Publications (1)

Publication Number Publication Date
AR125416A1 true AR125416A1 (en) 2023-07-12

Family

ID=87551293

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101055A AR125416A1 (en) 2020-04-05 2022-04-22 AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSOTROPHIES

Country Status (1)

Country Link
AR (1) AR125416A1 (en)

Similar Documents

Publication Publication Date Title
JP7444521B2 (en) A scalable method for producing recombinant adeno-associated virus (AAV) vectors in a serum-free suspension cell culture system suitable for clinical use.
Kobayashi et al. An improved reverse genetics system for mammalian orthoreoviruses
Davies et al. Potato spindle tuber viroid. XII. An investigation of viroid RNA as a messenger for protein synthesis
EA201991911A1 (en) METHODS AND COMPOSITIONS FOR TRANSFER OF GENES ON THE VASCULAR NET
JP2020505936A5 (en)
Oem et al. Molecular characterization of a Korean bovine parainfluenza virus type 3 isolate
JP2019536462A5 (en)
JP2019524140A5 (en)
US11028131B2 (en) Mutant of adeno-associated virus (AAV) capsid protein
DE59913833D1 (en) STRUCTURAL PROTEIN OF AAV, ITS MANUFACTURE AND USE
BR9813416A (en) Compositions and methods of recombinant nodaviruses
Li et al. Detection of border disease virus (BDV) in goat herds suffering diarrhea in eastern China
Cresawn et al. Comparative genomics of cluster O mycobacteriophages
ES2337768T3 (en) METHOD TO PURIFY ADENOVIRUS.
MX2022013819A (en) Modified adeno-associated virus 5 capsids and uses thereof.
JP7440045B2 (en) Nucleic acid-encapsulated AAV hollow particles
CN112041451A (en) AAV-based modular gene and protein delivery system
BR112020024992A2 (en) modified cas9 protein and its use
AR125416A1 (en) AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSOTROPHIES
Williams et al. Increased levels of B1 and B2 SINE transcripts in mouse fibroblast cells due to minute virus of mice infection
BR112023015177A2 (en) NUCLEIC ACID COMPRISING SMN1 AND MIR-23A FOR TREATMENT OF SPINAL MUSCULAR ATROPHY, EXPRESSION CASSETTE, EXPRESSION VECTOR, RECOMBINANT VIRUS, PHARMACEUTICAL COMPOSITION, RELATED USE AND METHOD
AR122404A1 (en) CAPSID VARIANTS AND USES THEREOF
CN112680443A (en) Promoter pCalm1 and application thereof
EP1328291A4 (en) Viruses targeted to hypoxic cells and tissues
Jalilian et al. An in-vitro transcription assay for development of Rotavirus VP7